US50127T1097
US50127T1097
Kura Oncology, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 942.98M EUR | 975.83M EUR | 721.64M EUR | 912.81M EUR |
Enterprise Value | 441.3M EUR | 930.04M EUR | 706.83M EUR | 784.17M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -4.51x | -- | -- | -- |
Price to Sales | 12.21x | 12.64x | 10.07x | 17.1x |
Price to Book | 19.49x | 20.15x | 6.69x | 5.24x |
EV/Revenue | 5.71x | 12.04x | 9.87x | 14.69x |
EV/EBITDA | -1.39x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | 599.35x |
EV/FCF | -- | -- | -- | 514.89x |
FCF Yield | -17.59% | -12.03% | -11.7% | 0.17% |